Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 2 Parkinson's papers of 103 | 0.85 |
| pathways Reactome | 1 pathway; mostly mitochondrial quality control | 1.00 |
No case: the score is under the bar. Receipt 9434
Sealed predictions
- LARS2 in dopamine neurons, braak+0.20 (p 0.602) → -0.16 (p 0.685)receipt 9441
Swarm cases
receipt 9441: LARS2 in dopamine neurons, braak
- power
- full sample +0.04 (p 0.861, n 18), 95% CI -0.43 to +0.50. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.13 (p 0.603, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.02 (p 0.928, n 18). could be the mix.
- skeptic
- leave-one-out range -0.04 to +0.18, sign flips 5; without severely affected donors +0.04 (p 0.861, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for LARS2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts